A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in BRAF V600E colorectal cancer (CRC) models. Patients with refractory BRAF V600–mutant metastatic CRC (mCRC) were treated with a selective RAF kinase...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: van Geel, Robin M.J.M., Tabernero, Josep, Elez, Elena, Bendell, Johanna C., Spreafico, Anna, Schuler, Martin, Yoshino, Takayuki, Delord, Jean-Pierre, Yamada, Yasuhide, Lolkema, Martijn P., Faris, Jason E., Eskens, Ferry A.L.M., Sharma, Sunil, Yaeger, Rona, Lenz, Heinz-Josef, Wainberg, Zev A., Avsar, Emin, Chatterjee, Arkendu, Jaeger, Savina, Tan, Eugene, Maharry, Kati, Demuth, Tim, Schellens, Jan H.M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546207/
https://ncbi.nlm.nih.gov/pubmed/28363909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0795
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi